Fosfomycin Trometamol Compared With an Alternative Active Antibiotic as Step-down Therapy for the Treatment of Acute Pyelonephritis Due to Escherichia Coli in Elderly Women : a Randomized, Multicenter, Non-inferiority Trial (FOSFOLD)
Fosfomycine trométamol comparé à un Autre Traitement Antibiotique Actif en Relais Pour le Traitement Des pyélonéphrites aiguës à Escherichia Coli Chez Les Femmes âgées : Essai randomisé, Multicentrique de Non infériorité
Acute pyelonephritis (APN) is among the most common bacterial infections in older women. Oral step-down antibiotic therapy may potentially be associated with toxicity, particularly with fluoroquinolones or trimethoprim-sulfamethoxazole, espcially in geriatric patients. The emergence of resistant strains reduces the choice of oral step-down treatment, thereby increasing the risk of nosocomial complications related to intravenous access and prolonged hospitalization.
Fosfomycin trometamol (FT) has broad activity against Enterobacterales, including resistant strains. It has an excellent safety profile and moderate ecological impact, and has been used for several years to treat cystitis. Recent studies have demonstrated its efficacy as an oral step-down therapy for the treatment of E.coli APN in younger women. Its efficacy in a geriatric population remains to be demonstrated.
The primary objective is to demonstrate the non-inferiority, in terms of clinical cure, of FT compared with an alternative active antibiotic as step-down therapy for E. coli APN in older women.
FOSFOLD is a national, multicenter, randomised, comparative, phase 3, non-inferiority trial (1:1), open-label with two parallel treatment groups. After 3 or 4 days of appropriate empirical antibiotic therapy, women aged 75 or over with E.coli APN will be randomised to receive either 3g of FT once daily or an alternative antibiotic treatment in accordance with current french guidelines, for a total of 10 days.
The primary endpoint is clinical cure at Day 17, i.e. 10 days after completion of antibiotic therapy.
If non-inferiority of FT is confirmed, it could provide a new therapeutic approach for oral step-down therapy in the older patients with APN. Its favorable tolerability profile could help prevent common geriatric complications, such as delirium, falls and malnutrition. Ultimately, it could help prevent some of the iatrogenic functional decline associated with hospitalisation.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Jérôme Lambert, MD PhD
- 전화번호: +33 +33 1 42 49 97 42
- 이메일: jerome.lambert@u-paris.fr
연구 연락처 백업
- 이름: Clara Pouchelon, MD
- 전화번호: +33 +33 1 40 36 73 67
- 이메일: clara.pouchelon@ght-gpne.fr
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Female.
- Age ≥ 75 years.
- Body temperature ≥ 38°C on at least once during the 72 hours preceding diagnosis.
- At least one new symptom among the following : urinary urgency, dysuria, increased urinary frequency, gross hematuria, burning on urination, spontaneous of provoked flank or suprapubic pain or urinary incontinence.
- Positive urine culture collected before initiation of antibiotic therapy defined as : ≥ 10,000 leukocytes/mL and monomicrobial culture with Escherichia coli ≥ 103 CFU/mL and susceptibility to FT,the empirical antibiotic,and at least one alternative antibiotic (active and not contraindicated), administered either orally (fluoroquinolone, amoxicillin, amoxicillin-clavulanic acid, or trimethoprim-sulfamethoxazole or, in the absence of an oral alternative, intravenously.
- Ability to reveive oral medication
- Favorable clinical course after 3 or 4 days of effective empirical antibiotic therapy, defined as resolution of fever (temperature < 38°C) and regression or reduction in the intensity and/or frequency of the clinical sign(s) present at the time of APN diagnosis, without the occurrence of any new symptoms.
Exclusion Criteria:
- Presence of an infectious focus other than the urinary tract.
- Severe infection and/or initial infectious complications, including septic shock, requirement for an emergency upper urinary tract intervention, or renal abscess.
- Indwelling urinary catheter, including bladder, ureteral, or nephrostomy catheters.
- Inability to take oral medication.
- Immunosuppression, including sold-organ transplant, ongoing immunosuppressive therapy, ongoing chemotherapy.
- Hypersensitivity to fosfomycin trometamol or to any of the excipients of the study medication
- End-stage chronic kidney disease with an estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m2.
- Lack of health insurance coverage.
- Patient under legal protection or guardianship.
- Absence of written informed consent from the patient or, if the patient is unable to provide consent, absence of agreement from the designated trusted person or a close relative.
- Participation in another interventional clinical research protocole
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Fosfomycin-trometamol (FT)
|
One sachet (3g), once daily, orally for 6 or 7 days, following 4 or 3 days, respectivelly of effective antibiotic therapy, for a total of 10 days of effective antibiotic treatment. |
|
활성 비교기: Alternative antibiotic treatment
|
Treatment will be selected at the investigator's discretion, in accordance with the 2017 recommandations of the French Society for Infectious Diseases (SPILF) and the 2025 French National Authority for Health (HAS) guidelines. Therapy will be administrated for 6 or 7 days (Day 1 - Day 6/7), following 4 or 3 days, respectively of effective antibiotic therapy. The total duration of effective antibiotic therapy will be 10 days. Injection antibiotic therapy will be offered in the absence of an active oral antibiotic option. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Clinical resolution
기간: Day 17
|
Clinical cure defined as :
|
Day 17
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Occurence of antibiotic-related adverse events
기간: Up to 37 days
|
Occurrence, nature, and severity of antibiotic-related adverse events, assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) scale. |
Up to 37 days
|
|
Occurence of geriatric complications
기간: Up to 37 days
|
|
Up to 37 days
|
|
Functional autonomy
기간: Up to 37 days
|
According to the Activities of Daily Living (ADL) scale: score ranges from 0 (complete dependence) to 6 (complete independence), with higher scores indicating greater independence in basic daily activities such as bathing, dressing, toileting, transferring and eating. |
Up to 37 days
|
|
Incidence of Infectious and urological complications
기간: Up to day 7
|
|
Up to day 7
|
|
Cumulative incidence of recurrent febrile or non-febrile urinary tract infectious (UTIs) (relapse or reinfection)
기간: From Day 17 to Day 37
|
|
From Day 17 to Day 37
|
|
Rate of hospitalization or rehospitalization following treatment for APN
기간: Up to day 37
|
Up to day 37
|
|
|
Length of hospital stay following randomization
기간: Up to day 37
|
Up to day 37
|
|
|
All-cause mortality
기간: Up to day 37
|
Up to day 37
|
|
|
Rate of rectal colonization with antibiotic-resistant Enterobacterales
기간: Up to day 37
|
fluoroquinolones, trimethoprim-sulfamethoxazole, fosfomycin, and third-generation cephalosporins |
Up to day 37
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- APHP240802
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .